# Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Series and Review of Literature

## TL;DR

This paper presents three cases of a rare blood cancer called BPDCN and describes the different treatments used for each patient.

## Contribution

The paper contributes by sharing real-world treatment approaches for BPDCN in the absence of established guidelines.

## Key findings

- One patient was treated with tagraxofusp followed by a stem cell transplant.
- Another patient received venetoclax alone as treatment.
- A third patient was treated with venetoclax and chemotherapy followed by a stem cell transplant.

## Abstract

Blastic plasmacytoid dendritic cell neoplasia (BPDCN) is a rare hematological malignancy. The heterogeneous presentation of this disease can make it difficult to diagnose. Another challenge presents itself when selecting the appropriate treatment as there are currently no treatment guidelines. We present three cases of BPDCN, each treated with a different treatment modality. The first-line treatment in one patient was tagraxofusp, followed by allogeneic stem cell transplant. The second patient was treated with venetoclax in monotherapy. The third patient was treated with a combination of venetoclax and intensive chemotherapy followed by allogeneic stem cell transplant as a consolidating therapy.